BlackRock, Inc. Reports 7.2% Stake in Recursion Pharmaceuticals (RXRX) via Schedule 13G/A

On April 24, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a significant stake in Recursion Pharmaceuticals, Inc. (RXRX). As of the event date on March 31, 2026, BlackRock beneficially owns 37,821,797 shares of Class A Common Stock, representing 7.2% of the company. This filing marks an increase from a previously reported 0.0% position, indicating a new substantial holding or a significant accumulation phase by the investment firm. BlackRock reported sole voting power over 37,178,542 shares and sole dispositive power over the full 37,821,797 shares. The filing was submitted as an amendment (Amendment No. 4) under Rule 13d-1(b), signifying that the shares were acquired in the ordinary course of business and not with the intent to influence or change the control of the issuer. Various BlackRock subsidiaries are listed as having an interest in the securities, though no single individual's interest exceeds 5% of the total outstanding shares.